 combined death,
stroke, and MI rate of ⱖ10% has been seen in octogenarians
treated with CAS.152,161 In the CREST study, CAS was
associated with an increased stroke risk in patients aged
⬎70 years9 and appeared to have a benefit compared with
CEA in patients aged ⬍70 years, although no other studies
have reported this association to date.
Because there is a demonstrable incidence